Navigation Links
Experimental Drug Slims Obese Monkeys
Date:11/9/2011

By Steven Reinberg
HealthDay Reporter

WEDNESDAY, Nov. 9 (HealthDay News) -- An experimental drug that targets and kills fat cells in the blood appears to help obese rhesus monkeys lose weight, a new study suggests.

In the future, this approach may help obese humans lose weight, according to the University of Texas M.D. Anderson Cancer Center researchers.

"Targeting blood vessels of white fat tissue is a novel conceptual approach against obesity," said study author Dr. Wadih Arap, the Stringer Professor of Medicine and Experimental Diagnostic Imaging at M.D. Anderson. "Adipotide is a new drug candidate against obesity to be translated into potential clinical applications in humans."

The report was published in the Nov. 9 issue of Science Translational Medicine.

The usual way drugs work to counter obesity is either by suppressing appetite or by increasing metabolism to try to burn calories faster, the investigators noted.

However, this new drug works by attaching itself to fat cells in the blood vessels and triggering a synthetic protein that causes the cell to die. These cells are then reabsorbed and metabolized, the researchers explained.

When the drug was tried on monkeys that were naturally obese they lost about 11 percent of their body weight over a month, Arap's team found.

In addition, the treated monkeys also improved their insulin resistance, which is a marker for developing type 2 diabetes. After treatment, the monkeys used 50 percent less insulin, the researchers found.

"Moreover, the monkeys lost 27 percent of abdominal white fat after Adipotide treatment," Arap said.

When the drug was given to lean monkeys they did not lose weight, suggesting that the drug may just select obese animals.

The drug did not have any adverse side effects, the researchers said, adding that the monkeys were "bright and alert throughout, interacting with caretakers and demonstrating no signs of nausea or food avoidance."

Within a month after treatment was stopped the monkeys started to gain weight again, the study authors noted.

The researchers are planning to test the drug on prostate cancer patients. These patients are prone to weight gain during hormone therapy, which can lead to arthritis-causing inactivity and a host of other health problems.

In addition, fat cells produce growth hormones that help cancer cells thrive, the researchers explained.

In this study, patients would receive injections of adipotide for 28 days.

"There is an increasingly clear scientific and medical interplay among obesity, metabolic syndrome and several human cancers, such as prostate, breast, colon, ovarian, among others," Arap said.

"Basically, we are in a cancer center and our group in particular has long been interested in this matter as a potentially new therapeutic in prostate cancer patients," he said.

Obesity expert Dr. David L. Katz, director of the Prevention Research Center at Yale University School of Medicine, said that "for those hopeful that pharmacotherapy might ultimately help us overcome epidemic obesity, this study serves up a preliminary dose of encouraging news."

This good news comes in a precautionary package of prior experience, Katz noted. "A study of nine weeks in a small group of genetically select monkeys is a very far cry from evidence in people, in the real world, over a meaningful span of time," he said.

Even weight-loss drugs that appeared to perform well in people over time like rimonabant and sibutramine have all led to disappointment, either because of waning effectiveness or toxicity, Katz noted.

"Adipotide may prove an exception to this rule, but believing it now would be the triumph of hope over experience," Katz said.

"This should not distract us from how much good we could reliably get done right now if we focused on turning what we already know about the power of feet and forks into what we routinely do," he added.

More information

For more information on obesity, visit the U.S. National Library of Medicine.

SOURCES: Wadih Arap, M.D., Ph.D., Stringer Professor of Medicine and Experimental Diagnostic Imaging, University of Texas M.D. Anderson Cancer Center, Houston; David L. Katz, M.D., M.P.H., director, Prevention Research Center, Yale University School of Medicine, New Haven, Conn.; Nov. 9, 2011, Science Translational Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Drug Offers Hope for Cystic Fibrosis Patients
2. Experimental Vaccine Shields Monkeys Against Ebola
3. Experimental targeted therapy shows early promise against medulloblastomas
4. Experimental nonsteroidal treatment of asthma shows promise
5. Experimental obesity drug avoids brain effects that troubled predecessors
6. Experimental treatments for cocaine addiction may prevent relapse
7. Experimental TB Test Called Fast and Accurate
8. Experimental Drug Shows Promise for Bone Marrow Disorder
9. Experimental Leukemia Drug Proves a Slam Dunk
10. Experimental Test May Spot Prostate Cancer Earlier, More Accurately
11. Experimental Drug Aids Kids With Nervous System Tumor
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Drug Slims Obese Monkeys
(Date:8/16/2017)... ... August 16, 2017 , ... Paul Vitenas, MD, FACS , ... Top Doctor. The annual list identifies the nation’s top physicians, in a variety of ... it to the top of Castle Connolly’s coveted ranking. , Castle Connolly is the ...
(Date:8/16/2017)... ... August 16, 2017 , ... SGNA Standards of Infection ... reprocessing cycle, both between patient procedures and before storage, is a requisite practice ... important to the prevention of disease transmission and nosocomial infection as cleaning and ...
(Date:8/16/2017)... ... 16, 2017 , ... Richard Strawn’s new book Surgical ... of a cancer diagnosis, surgery and recovery, the Psalms provided encouragement and hope, ... God shows love to those who are sick., Surgical Psalms contains 36 reflections ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... an opportunity for men and women to train as hospice volunteers. Volunteers provide ... life-limiting illness. For over 30 years, the agency has trained volunteers to be ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... and marketers of high-quality anti-aging skincare solutions, recently announced the launch of two ... are an affordable, yet effective alternative to expensive plastic surgery or in-patient cosmetic ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... OCEANSIDE, Calif. , Aug. 15, 2017  AOTI Inc. announced ... Advanced Oxygen Therapy Inc., has recently opened a New York City ... the ever-increasing usage of its unique Topical Wound Oxygen (TWO 2 ... approved by the Accreditation Commission for Health Care (ACHC) under the ... ...
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million ... continuing operations Second-quarter 2017 ... million Second-quarter 2017 Sterile ... Second-quarter 2017 adjusted diluted earnings ... to $0.93 Second-quarter 2017 ...
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc (NASDAQ: ... agreements to resolve virtually all known U.S. mesh product ... to resolve the known remaining U.S. claims at reasonable ... beginning in the fourth quarter of 2017 and continuing ... its second quarter 2017 results, the Company intends to ...
Breaking Medicine Technology: